Clinical trials: Chronic Disease (Physical)
- Condition Chronic Disease (Physical)
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
Chronic Kidney Disease(CKD)
Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects
The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects
- Trial name
- NCT06344936
- Testing
- HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Optimising the Propranolol Block Model
Optimising the propranolol block model
- Trial name
- NCT00549120
- Testing
- Propranolol, Salbutamol, Ipratropium
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01521390
- Testing
- GSK573719 62.5 mcg (one strip), GSK573719 62.5 mcg(two strips), GSK573719 125 mcg (one strip)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Narcotic Abuse, Opioid-related Disorders
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
This was a single-dose, randomized, double-blind, placebo-controlled, 3 way crossover study designed to evaluate the relative abuse potential of crushed EMBEDA® compared to morphine sulfate CR tablets and placebo in healthy male…
- Conditions
- Narcotic Abuse, Opioid-related Disorders, Analgesia, Chronic Pain
- Trial name
- NCT01595867
- Testing
- EMBEDA - morphine sulfate/ naltrexone hydrochloride, morphine sulfate CR crushed.
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pfizer
Central Venous Pressure
Comparison of a Non-Invasive Central Venous Pressure Device and Physical Examination in Patients With Chronic Kidney Disease
The primary objective of this study is to determine whether a correlation exists between the Mespere Non-Invasive Central Venous Pressure (NICVP) device for measuring central venous pressure (CVP), and assessment of CVP via…
- Trial name
- NCT01243515
- Testing
- Non-Invasive Central Venous Pressure monitor, Physical examination of jugular vein
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mespere Lifesciences Inc.
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
HepQuant tests are new liver tests that are being developed to accurately measure liver function with sensitivity and specificity while being safe and non-invasive.
- Trial name
- Repro (NCT01579162)
- Testing
- Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HepQuant, LLC
Chronic Liver Disease (CLD), Healthy Volunteers
Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function
The aim of the study is to confirm that the new generation state of the art breath analyzer gives equivalent results to the previous model of the Exalenz breath analyzer.
- Trial name
- NCT02187601
- Testing
- MPBA System, BreathID
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Renal Insufficiency, Chronic
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
The epoetin is a glycoprotein and endogenous hormone, which is primarily synthesized by specific epithelial cells lining the kidney peritubular capillaries, and regulates continuous formation of red blood cells.
- Trial name
- NCT03572647
- Testing
- Eritromax, Eprex
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
COPD, Asthma
AirSonea Wheeze Detection Study
The purpose of this study is to determine if the AirSonea device provides an objective assessment of breath sounds for the presence of wheeze in both medical and home environments.
- Trial name
- NCT01927172
- Testing
- AirSonea
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- iSonea
Obesity, Obesity, Abdominal
Impact of the Use of FeelWell™ Compression Garment on Individuals With a BMI ≥35
To assess the effect of wearing a custom-fitted, FDA-registered, Class I device, compression garment (Obesinov, S.A.R.L.) by an individual with a BMI ≥ 35 on his/her day-to-day quality of life over a period of one year.
- Conditions
- Obesity, Obesity, Abdominal, Mobility Limitation, Quality of Life
- Trial name
- NCT03798873
- Testing
- FeelWell™ Compression garment, Increase Mobility
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Feelwell Compression
Chronic Heart Failure With Reduced Ejection Fraction
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary…
- Trial name
- OUTSTEP-HF (NCT02900378)
- Testing
- LCZ696 (Sacubitril/Valsartan), Enalapril
- Where
- 119 sites in Belgium, Bulgaria and 17 more
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
Optimal clinical management in early stages of COPD is not established. Tiotropium has been shown to improve exercise tolerance during (CWR) cycle ergometry with GOLD stage II to IV COPD, improvements in constant speed treadmill…
- Trial name
- NCT01072396
- Testing
- Tiotropium
- Where
- 15 sites in United States, Canada
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
Renal Impairment Study for Oral EC5026
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1.
- Trial name
- NCT07694544
- Testing
- EC5026 oral tablet
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- EicOsis Human Health Inc.
Anemia, Chronic Kidney Disease
LEARN-6™: A Prospective, Observational Nursing Home Study
This is a prospective, multicenter, observational, hypothesis-generating study exploring mobility, Quality of Life and other physical performance measures among older, long-term stay Nursing Home residents with CKD, with versus…
- Trial name
- NCT00727571
- Testing
- Observations
- Volunteers
- 815 people, healthy volunteers welcome
- Sponsor
- Amgen